Yes, and with two ongoing 'supported' covid trials - a favorable share structure of 47M (sporting a $50M-marketcap trading in a sea of $500M+-marketcap peer stocks) - a reasonable quarterly burn - don't find many like this very often?
If ARPO were to fill the .80 downgap leftover from May, it would most likely become my #2 position right behind current #1 position NBIO...sporting a $5M-marketcap in a sea of $500M+-marketcap peer stocks.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.